Financial Performance - The company's revenue for Q1 2025 was ¥114,446,404.92, a decrease of 17.10% compared to ¥138,059,120.72 in the same period last year[5] - Net profit attributable to shareholders was ¥10,326,085.35, down 72.38% from ¥37,381,597.20 year-on-year[5] - Basic earnings per share fell by 69.23% to ¥0.04 from ¥0.13 in the previous year[5] - Total operating revenue decreased to ¥114,446,404.92 from ¥138,059,120.72, a decline of approximately 17.1% year-over-year[20] - Net profit for the period was ¥10,326,085.35, down from ¥37,381,597.20, a decrease of approximately 72.3% year-over-year[21] - The total comprehensive income for the period was ¥10,326,085.35, down from ¥37,381,597.20, reflecting a decrease of approximately 72.3% year-over-year[21] - Basic and diluted earnings per share decreased to ¥0.04 from ¥0.13, a decline of about 69.2% year-over-year[22] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 57.74%, amounting to ¥6,056,981.76 compared to ¥14,331,076.29 in Q1 2024[11] - Cash and cash equivalents at the end of the period were ¥494,729,887.37, down from ¥1,663,102,024.22, a decrease of approximately 70.3% year-over-year[24] - The company's cash and cash equivalents decreased to ¥494,729,887.37 from ¥543,139,791.63, representing a decline of approximately 8.5%[16] Assets and Liabilities - Total assets at the end of Q1 2025 were ¥2,471,565,643.49, a slight decrease of 0.69% from ¥2,488,655,694.01 at the end of the previous year[5] - Total current assets amounted to ¥1,859,505,802.43, slightly down from ¥1,874,616,455.24, indicating a decrease of about 0.8%[16] - Total liabilities decreased to ¥150,658,217.06 from ¥178,967,160.85, a reduction of approximately 15.8%[17] - The company's total assets stood at ¥2,471,565,643.49, down from ¥2,488,655,694.01, indicating a decrease of about 0.7%[17] - Non-current assets totaled ¥612,059,841.06, slightly down from ¥614,039,238.77, reflecting a decrease of approximately 0.3%[17] Accounts Receivable and Inventory - The company reported a significant increase in accounts receivable by 35.76%, reaching ¥66,014,945.08 compared to ¥48,626,872.60 in the previous year[9] - Accounts receivable increased to ¥66,014,945.08 from ¥48,626,872.60, reflecting a growth of approximately 35.7%[16] - Inventory decreased to ¥133,728,313.29 from ¥137,851,042.47, showing a decline of about 3.0%[16] Research and Development - Research and development expenses decreased by 39.87% to ¥6,579,414.49 from ¥10,942,220.83 in Q1 2024[10] - Research and development expenses decreased to ¥6,579,414.49 from ¥10,942,220.83, a reduction of about 39.5% year-over-year[20] Government Subsidies and Financial Improvements - The company received government subsidies amounting to ¥1,620,203.03, an increase of 170.27% compared to ¥599,479.25 in the same period last year[10] - Financial expenses showed a significant improvement, with a net income of -¥2,483,621.83 compared to -¥17,739,443.07 in the previous period[20] - The company recorded a fair value change income of ¥7,074,652.79, up from ¥947,916.62, indicating a substantial increase[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,753, with the largest shareholder holding 38.25% of the shares[12] Reporting and Accounting Standards - The first quarter report of Hubei Hendi Pharmaceutical Co., Ltd. is unaudited[25] - The new accounting standards will be implemented starting from 2025[25] - The financial statement items related to the first year of the new accounting standards will be adjusted[25] - The board of directors announced the first quarter report on April 25, 2025[25]
亨迪药业(301211) - 2025 Q1 - 季度财报